Classic Review,to regulate appetite and energy metabolism

Glucose-dependent insulinotropic peptide (GIP), also known as gastric inhibitory polypeptide, is a vital gastrointestinal hormone that plays a significant role in regulating glucose metabolism and nutrient handling within the body. As a member of the secretin family of hormones, its primary function is intrinsically linked to the presence of nutrients in the small intestine, particularly fats and carbohydrates. Understanding GIP's multifaceted roles is crucial for comprehending how our bodies manage energy and maintain stable blood sugar levels.

One of the most well-established functions of glucose-dependent insulinotropic peptide is its potentiation of insulin secretion. When food is consumed, GIP is released from specialized K-cells in the duodenum and jejunum. This release is directly proportional to the amount of glucose and fat present. Upon reaching the pancreas, GIP binds to its specific receptor on beta cells, thereby stimulating the release of insulin from the beta cells in the pancreas. This insulin release is "glucose-dependent," meaning it is most pronounced when blood glucose levels are elevated, helping to prevent postprandial hyperglycemia. This incretin effect, where oral glucose elicits a greater insulin response than intravenous glucose, is largely attributed to GIP and its counterpart, GLP-1.

Beyond its direct impact on insulin, GIP exhibits several other critical functions. It inhibits secretion of acid in the stomach and suppresses gastric motility, which helps to slow down the digestion process and allow for more efficient nutrient absorption in the small intestine. Furthermore, GIP enhances adipose tissue metabolism and potentiates insulin secretion and facilitates intestinal nutrient absorption. In concert with insulin, GIP directly enhances adipocyte uptake of glucose, contributing to its role in nutrient deposition and storage. This means that GIP can influence how our bodies store energy, particularly in the form of fat. Indeed, research suggests that GIP promotes fat deposition in adipose tissue, a mechanism that, while beneficial for energy storage, can contribute to fat-induced obesity under certain conditions, as highlighted in studies by Y Seino.

The glucose-dependent insulinotropic peptide function extends to its influence on glucagon secretion. Unlike GLP-1, which suppresses glucagon, GIP increases glucagon secretion from alpha cells in the pancreas, particularly during fasting and hypoglycemic conditions, where it has little to no effect on insulin secretion. This dual action on both insulin and glucagon makes GIP a physiological bifunctional blood glucose stabilizer with diverging glucose-dependent effects on the two main pancreatic glucoregulatory cells.

The intricate mechanism of action of GIP also involves signaling pathways that influence appetite and energy metabolism. Research indicates that GIP can regulate appetite and energy metabolism by acting in the brain. This suggests a broader role for GIP in overall metabolic control, not just glucose homeostasis.

In recent years, GIP has emerged as a pivotal therapeutic target in metabolic disorders such as type 2 diabetes and obesity. The development of GIP receptor agonists and dual GIP/GLP-1 receptor agonists has shown promising results in improving glycemic control, promoting weight loss, and enhancing lipid profiles. This is partly due to the combined effects of GIP and GLP-1, where GLP-1 suppresses, and GIP increases glucagon secretion, and both peptides have distinct yet complementary roles in metabolic regulation. For instance, while GLP-1 delays gastric emptying and reduces food intake, GIP enhances adipose tissue metabolism. Understanding the nuanced glucose-dependent insulinotropic peptide function is therefore paramount for developing effective treatments for these widespread conditions.

In summary, the function of glucose-dependent insulinotropic peptide is complex and vital for maintaining metabolic health. From its primary role in insulin secretion to its influence on fat deposition, appetite regulation, and glucagon secretion, GIP is a key player in our body's intricate hormonal network. Its ability to enhance glucose uptake and storage, along with its interactions with other incretin hormones like GLP-1, underscores its importance as a target for therapeutic interventions aimed at managing metabolic diseases. The ongoing research into glucose-dependent insulinotropic peptide (GIP) continues to unveil its profound impact on nutrient handling and overall well-being.